FDA In Brief: FDA Issues Two Draft Guidances to Help Facilitate the Development of Adjuvant Treatment for Kidney and Bladder Cancer |
Today, the U.S. Food and Drug Administration issued two draft guidances that, if finalized, will provide recommendations to sponsors seeking to develop drugs and biologics for adjuvant treatment of renal cell carcinoma and bladder cancer. “Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment,” provides draft guidance to sponsors regarding the development of drugs and biologics for the adjuvant treatment of renal cell carcinoma. “Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment,” provides draft guidance to sponsors developing drugs and biologics for the adjuvant treatment of muscle-invasive bladder cancer. |
No hay comentarios:
Publicar un comentario